Use: Test for the laboratory diagnosis of myasthenia gravis (MG)

Limitations: This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration. In rare cases AChR antibodies can be found in patients with other autoimmune disorders or with thymoma without MG. The causative autoantibody cannot be identified in up to 10 percent of patients with MG.

Methodology: AChR-binding assay and blocking antibody: radioimmunoassay (RIA); AChR-modulating antibody: Flow Cytometry